Patrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.
Patrick Forde, MBBCh
Advertisement
Patrick Forde, MBBCh, is the codirector, Division of Upper Aerodigestive Malignancies, and professor of oncology at Johns Hopkins Medicine.
Articles by Patrick Forde, MBBCh
Patrick Forde, MBBCh, discusses the results of the TRIDENT-1 trial that led to the approval of repotrectinib for patients with metastatic ROS1 positive NSCLC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
